$ALT

Altimmune Inc (ALT) reported a strong cash position of approximately USD535 million as of April 2026, bolstered by a USD225 million public offering. Despite increased R&D and G&A expenses leading to a net loss of USD22.6 million in Q1 2026, the company's financial runway is secured through the Phase III MASH 52-week data readout in 2029. Pemvidutide, their lead drug candidate, has received Breakthrough Therapy designation, and its Phase II IMPACT trial showed promising efficacy, with Phase III trials aligned with regulatory feedback from the FDA and EMA.